Does the RIFLE Classification Improve Prognostic Value of the APACHE II Score in Critically Ill Patients?
Table 2
Demographic and clinical characteristics of critically ill patients defined by the RIFLE classification.
Variable
Age (years) (±DP)
66 (±16.7)
Females N (%)
107 (53.5)
Days of ICU stay (IQR)
12 (4–17)
Comorbidities on admission N (%)
DM + SH or DLP
99 (49.5)
Cancer/Oncology Therapy
34 (17)
NYHA class IV
06 (3)
Immunossuppression
3 (1.5)
Surgical Admission N (%)
ICU Admission
65 (32.5)
Compromised system N (%)
Respiratory
54 (27.3)
Neurology
52 (26.3)
Heart
43 (21.7)
Polytrauma
02 (1)
Other
47 (23)
Use of Mechanical Ventilation N (%)
79 (39.5)
Vasoactive drugs N (%)
55 (27.5)
Diuretic use N (%)
54 (27)
Mean arterial pressure (SD)
94 (±26.7)
Serum creatinine (minimum–maximum)
1 (0.2–9.8)
APACHE II score (±SD)
13 (±6.6)
Not patched APCHE II renal (±SD)
12.3 (±5.9)
SOFA (IQR)
3 (0–5)
Nonrenal SOFA (IQR)
2 (0–4)
TISS-28 (±SD)
21 (±7.3)
Glasgow (±SD)
13.3 (±3)
RIFLE: Risk, Injury, Failure, Loss, End: DM: Diabetes Mellitus; Hypertension: hypertension DLP: dyslipidemia; NYHA class IV: heart failure functional class IV; SOFA: Sequential Organ Failure Assessment Score; Nonrenal SOFA: Sequential Organ Failure Assessment Score without the score for renal failure. APACHE II: Acute Physiology and Chronic Health Evaluation version II. Nonrenal APACHE II: APACHE II score without referring to kidney failure. TISS-28: The Therapeutic Intervention Score System; Glasgow: Glasgow Coma Scale; SD: standard deviation; IQR: Interquartile range.
